When nonplatinum is the answer: The role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Trabectedin + pegylated liposomal doxorubicin (PLD) offers a well tolerated and effective nonplatinum, nontaxane alternative for treatment of ovarian cancer patients with a treatment-free interval after platinum beyond 6 months, especially for those relapsing between 6 and 12 months and those who are not candidates to receive platinum-based therapy. Using the nonplatinum trabectedin + PLD combination gives patients time to recover from platinum-related toxicities and may restore platinum sensitivity in tumor cells. The sequence effect, by which intercalation of trabectedin + PLD between platinum regimens may enhance the activity of next platinum and improve survival, is currently under investigation in the Phase III prospective INternational OVArian cancer patients Trial with YONdelis.

Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalFuture Oncology
Volume13
Issue number23S
DOIs
Publication statusPublished - Oct 1 2017

Keywords

  • recurrent ovarian cancer
  • sequence effect
  • trabectedin
  • treatment-free interval

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'When nonplatinum is the answer: The role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this